Scarica l'app Stockscreener
56.68
0.30%
-0.17
Dopo l'orario di chiusura:
56.00
-0.68
-1.20%
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN) - Finviz
Double-digit Revenue Growth Till 2030 Drives BioMarin’s (BMRN) Bullish Thesis - Insider Monkey
Double-digit Revenue Growth Till 2030 Drives BioMarin's (BMRN) Bullish Thesis - Finviz
BioMarin to offer $850 million in notes to fund Amicus acquisition By Investing.com - Investing.com Nigeria
BioMarin Plans to Offer $850 Million in Senior Unsecured Notes - Intellectia AI
BioMarin to offer $850 million in notes to fund Amicus acquisition - Investing.com
BioMarin lines up $2B loan, $800M facility for Amicus deal - Stock Titan
10 Cheap Stocks with Huge Upside Potential - Insider Monkey
BioMarin Plans $850M Senior Unsecured Notes Offering - Intellectia AI
Y Intercept Hong Kong Ltd Sells 51,159 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Sector Gamma AS Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Rakuten Investment Management Inc. Acquires New Shares in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Is Quietly Exploding — Is BMRN the Biotech Stock You’re Sleeping On? - AD HOC NEWS
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Presents a Compelling Value Investment Case - Chartmill
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
BioMarin vets form Mendra to ‘modernize’ rare disease drug development - BioPharma Dive
Ex-BioMarin execs launch Mendra with $82M to 'modernise' rare disease R&D - FirstWord Pharma
Liquidity Mapping Around (BMRN) Price Events - Stock Traders Daily
BioMarin Pharmaceutical (NASDAQ:BMRN) Raised to Buy at Canaccord Genuity Group - MarketBeat
Campbell & CO Investment Adviser LLC Trims Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Biotech Stocks Facing FDA Decision In February 2026 - RTTNews
BioMarin stock rating upgraded by Canaccord Genuity on Amicus acquisition By Investing.com - Investing.com Nigeria
BioMarin stock rating upgraded by Canaccord Genuity on Amicus acquisition - Investing.com UK
BioMarin names new chief accounting officer - MSN
Aug Volume: Is BioMarin Pharmaceutical Inc stock risky to hold nowDividend Hike & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Sumitomo Mitsui Trust Group Inc. Has $24.48 Million Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Is BioMarin (BMRN) Elevating Digital Strategy To Sharpen Its Innovation And Efficiency Edge? - Sahm
Korea’s Ildong promotes Chae Joon Lee to co-CEO - BioCentury
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Zacks.com featured highlights include Universal Health Services, PNC Financial Services, Global Payments and BioMarin Pharmaceutical - The Globe and Mail
BioMarin’s PALace Study: Long-Term Safety Check on Palynziq and What It Means for Investors - TipRanks
11 potential new genetic-disease medicines as BioMarin maps $4B push - Stock Titan
BioMarin drops development of liver, lung disease asset - MSN
A Look At BioMarin Pharmaceutical (BMRN) Valuation After New Chief Digital And Information Officer Appointment - Sahm
Humana Partners With Atlas to Enhance Cancer Care for Seniors - TradingView — Track All Markets
4 Value Stocks to Buy As Wall Street Weighs Trump Policies - The Globe and Mail
BioMarin names Arpit Davé as Chief Digital and Information Officer - The American Bazaar
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - sharewise.com
BMRN or TARS: Which Is the Better Value Stock Right Now? - Yahoo Finance
Is BioMarin Pharmaceutical (BMRN) a Great Value Stock Right Now? - Yahoo Finance
BioMarin Pharmaceutical touts $3.2B 2025 revenue, Voxzogo surge and Amicus deal at JPM Conference - MarketBeat
BioMarin Pharmaceutical Reports Preliminary 2025 Revenue, Details Asset Write-Down - marketscreener.com
BioMarin appoints Arpit Davé as chief digital and information officer By Investing.com - Investing.com Nigeria
Lobbying Update: $30,000 of BIOMARIN PHARMACEUTICAL INC. lobbying was just disclosed - Quiver Quantitative
BioMarin appoints Arpit Davé as chief digital and information officer - Investing.com
Biomarin Pharmaceutical Inc estimates $3.2 billion in total revenues for FYSEC filing - marketscreener.com
BioMarin Pharmaceutical Names Arpit Dave Chief Digital and Information Officer - marketscreener.com
BMRN: Strong growth, pipeline progress, and Amicus integration position for sustained double-digit CAGR - TradingView
BioMarin Appoints Arpit Davé Chief Digital and Information Officer - PR Newswire
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - MSN
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo Finance
HC Wainwright: BioMarin’s (BMRN) Amicus acquisition stabilizes cash flow while Voxzogo remains near-term driver - MSN
Why (BMRN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Veeva and BioMarin form strategic partnership to accelerate therapies By Investing.com - Investing.com Nigeria
How BioMarin Pharmaceutical Inc. (BM8) stock compares with tech leaders2025 EndofYear Setup & AI Powered Buy/Sell Recommendations - ulpravda.ru
Veeva and BioMarin Form Long-Term Strategic Partnership - Sahm
2.49%
4.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):